Xtant Medical’s X-spine Systems subsidiary received FDA 510(k) clearance to market the Xspan™ Laminoplasty Fixation System, intended for use in the lower cervical and upper thoracic spine. Initial limited launch is slated for 2Q16.
Xtant Medical estimates the worldwide laminoplasty market to be US $110MM.
Received CE Mark approval for the Aranax™ cervical plate and the Irix-A™ standalone anterior lumbar fusion device
Entered into a distribution agreement with Vivex Biomedical to commercialize OsteoVive™ viable cell allograft
Xtant Medical's X-spine Systems subsidiary received FDA 510(k) clearance to market the Xspan™ Laminoplasty Fixation System, intended for use in the lower cervical and upper thoracic spine. Initial limited launch is slated for 2Q16.
Xtant Medical estimates the worldwide laminoplasty market to be US $110MM.
Xtant Medical’s X-spine Systems subsidiary received FDA 510(k) clearance to market the Xspan™ Laminoplasty Fixation System, intended for use in the lower cervical and upper thoracic spine. Initial limited launch is slated for 2Q16.
Xtant Medical estimates the worldwide laminoplasty market to be US $110MM.
Copy to clipboard 
